Effect of omalizumab on angioedema in H ₁ ‐antihistamine‐resistant chronic spontaneous urticaria patients: results from X‐ <scp>ACT</scp> , a randomized controlled trial

Abstract

Omalizumab was an effective treatment option for patients with moderate-to-severe CSU symptoms and angioedema unresponsive to high doses of antihistamine treatment.